Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma In the article accompanying this editorial, Jensen et al 20 provide an update on the READ ...

Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment ...

CNS Pharmaceuticals (NASDAQ: CNSP) , focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in ...

Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.

For patients with operative triple-negative breast cancer, a multigene signature can help tailor adjuvant chemotherapy.

Health experts want blood- and breast-cancer patients prescribed exercise to mitigate heart damage during treatment.

A multigene signature can be used to guide decisions about adjuvant therapy in patients with triple-negative breast cancer, data suggest.

2024 年第 47 届 圣安东尼奥乳腺癌研讨会（San Antonio Breast Cancer Symposium，SABCS）将于 2024 年 12 月 10-13 日在美国圣安东尼奥隆重召开。SABCS ...

蒽环类药物（anthracyclines）的应用在肿瘤治疗的历史长河中具有里程碑式的意义，其应用范围广泛。尽管在靶向治疗与免疫治疗等新兴疗法日新月异的当下，蒽环类药物依然在多种实体肿瘤及血液恶性肿瘤治疗中发挥着重要作用。那么，蒽环类药物具体涵盖了哪些 ...

Strong preclinical evidence of Annamycin's potential for treating pancreatic cancer presented at AACR expands collaboration ...

The US regulator has approved the first-line use of Vanflyta (quizartinib) in combination with standard cytarabine/anthracycline induction therapy and cytarabine consolidation therapy for these ...